83 related articles for article (PubMed ID: 37334373)
1. A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine.
Choi YM; Kim DH; Jang J; Kim BJ
Front Immunol; 2023; 14():1155637. PubMed ID: 37334373
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.
Qi R; Fu R; Lei X; He J; Jiang Y; Zhang L; Wu Y; Wang S; Guo X; Chen F; Nie M; Yang M; Chen Y; Zeng J; Xu J; Xiong H; Fang M; Que Y; Yao Y; Wang Y; Cao J; Ye H; Zhang Y; Zheng Z; Cheng T; Zhang J; Lin X; Yuan Q; Zhang T; Xia N
J Hepatol; 2024 May; 80(5):714-729. PubMed ID: 38336348
[TBL] [Abstract][Full Text] [Related]
3. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
Meng CY; Sun S; Liang Y; Xu H; Zhang C; Zhang M; Wang FS; Fu YX; Peng H
Gut; 2023 Aug; 72(8):1544-1554. PubMed ID: 36316098
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
Zhang Y; Bourgine M; Wan Y; Song J; Li Z; Yu Y; Jiang W; Zhou M; Guo C; Santucci D; Liang X; Brechot C; Zhang W; Charneau P; Wu H; Qiu C
J Hepatol; 2024 Jan; 80(1):31-40. PubMed ID: 37827470
[TBL] [Abstract][Full Text] [Related]
5. Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine.
Liu X; Min Q; Song H; Yue A; Li Q; Zhou Q; Han W
J Nanobiotechnology; 2023 Nov; 21(1):441. PubMed ID: 37993870
[TBL] [Abstract][Full Text] [Related]
6. Potentiating the Immune Responses of HBsAg-VLP Vaccine Using a Polyphosphoester-Based Cationic Polymer Adjuvant.
Liu X; Liu Y; Yang X; Lu X; Xu XN; Zhang J; Chen R
ACS Appl Mater Interfaces; 2023 Oct; 15(42):48871-48881. PubMed ID: 37816068
[TBL] [Abstract][Full Text] [Related]
7. mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.
De Pooter D; Pierson W; Pourshahian S; Dockx K; De Clerck B; Najera I; Davis H; Van Gulck E; Boden D
Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543871
[TBL] [Abstract][Full Text] [Related]
8. Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism.
Ma S; Lv M; Chen X; Zang G; Tang Z; Zhang Y; Hu W
Antiviral Res; 2023 Aug; 216():105662. PubMed ID: 37393054
[TBL] [Abstract][Full Text] [Related]
9. Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.
Su J; Harati Taji Z; Kosinska AD; Ates Oz E; Xie Z; Bielytskyi P; Shein M; Hagen P; Esmaeili S; Steiger K; Protzer U; Schütz AK
JHEP Rep; 2024 Apr; 6(4):100997. PubMed ID: 38425450
[TBL] [Abstract][Full Text] [Related]
10. Mathematical Models of Early Hepatitis B Virus Dynamics in Humanized Mice.
Ciupe SM; Dahari H; Ploss A
Bull Math Biol; 2024 Apr; 86(5):53. PubMed ID: 38594319
[TBL] [Abstract][Full Text] [Related]
11. Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels.
Conceição-Neto N; Pierson W; Vacca M; Beyens M; De Clerck B; Aerts L; Voeten B; De Pooter D; Verschueren L; Dockx K; Vandenberk M; De Troyer E; Verwilt K; Van Hove C; Verslegers M; Bosseler L; Crabbe M; Krishna V; Nájera I; Van Gulck E
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140229
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis.
Zhang LL; Guo J; Duan K
Cent Eur J Immunol; 2019; 44(4):455-462. PubMed ID: 32140059
[TBL] [Abstract][Full Text] [Related]
13. Establishment of Humanized Mice for the Study of HBV.
Lai F; Wee CYY; Chen Q
Front Immunol; 2021; 12():638447. PubMed ID: 33679796
[TBL] [Abstract][Full Text] [Related]
14. Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg.
Zhang S; Sang X; Hou D; Chen J; Gu H; Zhang Y; Li J; Yang D; Zhu H; Yang X; Wang F; Zhang C; Chen X; Zen K; Zhang CY; Hong Z
Biomaterials; 2019 Jul; 210():83-93. PubMed ID: 31078314
[TBL] [Abstract][Full Text] [Related]
15. Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus.
Malecki M; Putzer E; Quach C; Dodivenaka C; Tombokan X
Clin Transl Med; 2016 Dec; 5(1):44. PubMed ID: 27905089
[TBL] [Abstract][Full Text] [Related]
16. Identification of dihydroquinolizinone derivatives with nitrogen heterocycle moieties as new anti-HBV agents.
Song H; Yang S; Wu S; Qin X; Wang Y; Ma X; Gong J; Wei M; Wang A; Wang M; Lan K; Guo J; Liu M; Chen X; Li Y; Lv K
Eur J Med Chem; 2024 Mar; 268():116280. PubMed ID: 38458109
[TBL] [Abstract][Full Text] [Related]
17. Havachoobe (Onosma dichroanthum Boiss) Root Extract Decreases the Hepatitis B Virus Surface Antigen Secretion in the PLC/PRF/5 Cell Line.
Mohebbi A; Azadi F; Hashemi MM; Askari FS; Razzaghi N
Intervirology; 2020 Dec; ():1-5. PubMed ID: 33321500
[TBL] [Abstract][Full Text] [Related]
18. Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B.
Malecki M; Sabo C; Foorohar A; Tombokan X
Clin Transl Med; 2016 Dec; 5(1):32. PubMed ID: 27539579
[TBL] [Abstract][Full Text] [Related]
19. Transient Co-Expression of Bioactive Murine Interferon-Gamma and HBsAg in Tobacco and Lettuce Leaves.
Mohammadzadeh S; Amiri M; Ehsani P
Avicenna J Med Biotechnol; 2023; 15(4):232-238. PubMed ID: 38078343
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice.
Lan W; Wang Y; Zhou Z; Sun X; Zhang Y; Zhang F
Metabolites; 2022 Mar; 12(4):. PubMed ID: 35448475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
